00:00 / 00:00
|ACE INHIBITORS TO TREAT MYASTHENIA GRAVIS|
|DRUG NAME||neostigmine (Bloxiverz), pyridostigmine (Mestinon, Regonol)|
|MECHANISM OF ACTION||Inhibit acetylcholinesterase, resulting in a buildup of acetylcholine in the synaptic cleft|
|ROUTE(S) OF ADMINISTRATION|
|CONTRAINDICATIONS AND CAUTIONS|
|NURSING CONSIDERATIONS: |
ACE INHIBITORS TO TREAT MYASTHENIA GRAVIS
|ASSESSMENT AND MONITORING||Assessment|
Myasthenia gravis is an autoimmune disorder caused by antibodies that bind to and destroy acetylcholine receptors on the surface of skeletal muscle cells, resulting in fatigue and muscle weakness due to impaired muscle contractions.
Although there’s no cure, certain medications, called acetylcholinesterase inhibitors, can be used to help mitigate some of the symptoms and improve the client’s quality of life.
Now, the most commonly used acetylcholinesterase inhibitors for myasthenia gravis are neostigmine and pyridostigmine. These medications can be administered orally, intravenously, or intramuscularly, while neostigmine can be also given subcutaneously to children.
Once absorbed into the bloodstream, acetylcholinesterase inhibitors travel to the skeletal muscles and inhibit the enzyme acetylcholinesterase, which normally breaks down the neurotransmitter acetylcholine.
This helps counteract the effect of acetylcholine receptor antibodies, and ultimately results in improved muscle strength and contraction.
Acetylcholinesterase inhibitors are a class of drugs that are used to treat myasthenia gravis. These drugs work by inhibiting the action of acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine. Acetylcholine is responsible for mediating muscle contraction. By inhibiting its breakdown, acetylcholinesterase inhibitors increase the amount of acetylcholine available for muscle contraction, which leads to improved muscle strength.
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.